PTC Therapeutics | PTCT - Current Liabilities


PTC Therapeutics reported $771.07M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Cytokinetics USD 181.43M 17.76M Jun/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.02B 1.54B Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026